[1] 扈东营,姜伟伟,李航,等.侵袭性念珠菌感染流行病学现状和治疗进展[J].世界临床药物,2020,41(5):323-328.
[2] 张欠欠,罗传玉,陈嘉琪,等.白念珠菌感染现状及抗真菌药物研究进展[J].中国真菌学杂志,2021,16(5):356-360.
[3] 中国成人念珠菌病诊断与治疗专家共识组. 中国成人念珠菌病诊断与治疗专家共识[J]. 中华内科杂志,2020,59(1):5-17.
[4] HOVING J C,BROWN G D,GOMEZ B L,et al. AIDS-related mycoses: Updated progress and future priorities[J]. Trends Microbiol,2020,28(6):425-428.
[5] SANGENITO L S,D'AVILA-LEVY C M,BRANQUINHA M H,et al. Repositioning drug strategy against Trypanosoma cruzi: lessons learned from HIV aspartyl peptidase inhibitors[J]. Mem Inst Oswaldo Cruz,2022,117:e210386.DOI: 10.1590/0074-02760210386.
[6] BEKTIĆ J,LELL C P,FUCHS A,et al. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro[J]. FEMS Immunol Med Microbiol,2001,31(1):65-71.
[7] MAYER F L,WILSON D,HUBE B. Candida albicans pathogenicity mechanisms[J]. Virulence, 2013,4(2):119-128.
[8] CASTILHO D G,CHAVES A F A,NAVARRO M V,et al. Secreted aspartyl proteinase (PbSap) contributes to the virulence of Paracoccidioides brasiliensis infection[J]. PLoS Negl Trop Dis, 2018,12(9):e6806.
[9] NAGLIK J R,CHALLACOMBE S J,HUBE B. Candida albicans secreted aspartyl proteinases in virulence and pathogenesis[J]. Microbiol Mol Biol Rev,2003,67(3):302-400,428.
[10] CALUGI C, GUARNA A,TRABOCCHI A. Insight into the structural similarity between HIV protease and secreted aspartic protease-2 and binding mode analysis of HIV-Candida albicans inhibitors[J]. J Enzyme Inhib Med Chem,2013,28(5):936-943.
[11] DOSTAL J,BRYNDA J,HRUSKOVA-HEIDINGSFELDOVA O,et al. The crystal structure of protease Sapp1p from Candida parapsilosis in complex with the HIV protease inhibitor ritonavir[J]. J Enzyme Inhib Med Chem,2012,27(1):160-165.
[12] SANTOS A L S,BRAGA-SILVA L A,GONÇALVES D S, et al. Repositioning lopinavir, an HIV protease inhibitor,as a promising antifungal drug: lessons learned from Candida albicans—in silico,in vitro and in vivo approaches[J]. JoF,2021,7(6):424.
[13] BRAGA-SILVA L A,MOGAMI S S V,VALLE R S,et al. Multiple effects of amprenavir against Candida albicans[J]. FEMS yeast research,2010,10(2):221-224.
[14] PALMEIRA V F,GOULART F R V,GRANATO M Q,et al. Fonsecaea pedrosoi sclerotic cells: secretion of aspartic-type peptidase and susceptibility to peptidase inhibitors[J]. Front Microbiol, 2018,9:1383.DOI:10.3389/fmicb.2018.01383.
[15] GRANATO M Q,SOUSA I S,ROSA T,et al. Aspartic peptidase of Phialophora verrucosa as target of HIV peptidase inhibitors: blockage of its enzymatic activity and interference with fungal growth and macrophage interaction[J]. J Enzyme Inhib Med Chem, 2020,35(1):629-638.
[16] REBELLO K M, ANDRADE-NETO V V, ZUMA A A, et al. Lopinavir, an HIV-1 peptidase inhibitor, induces alteration on the lipid metabolism of Leishmania amazonensis promastigotes[J]. Parasitology,2018,145(10):1304-1310.
[17] SANGENITO L S,PEREIRA M G,SOUTO-PADRON T,et al. Lopinavir and nelfinavir induce the accumulation of crystalloid lipid inclusions within the reservosomes of Trypanosoma cruzi and inhibit both aspartyl-type peptidase and cruzipain activities detected in these crucial organelles[J]. Trop Med Infect Dis,2021,6(3):120.
[18] MUNDODI V,CHOUDHARY S,SMITH A D,et al. Global translational landscape of the Candida albicans morphological transition[J]. G3 (Bethesda),2021,11(2):jkaa043.
[19] KADOSH D. Regulatory mechanisms controlling morphology and pathogenesis in Candida albicans[J]. Curr Opin Microbiol,2019,52:27-34.DOI:DOI: 10.1016/j.mib.2019.04.005.
[20] SANTOS A L S,BRAGA-SILVA L A. Aspartic protease inhibitors: effective drugs against the human fungal pathogen Candida albicans[J].Mini Rev Med Chem,2013,13(1):155.
[21] ROMO J A,PIERCE C G,CHATURVEDI A K,et al. Development of anti-virulence approaches for candidiasis via a novel series of small-molecule inhibitors of Candida albicans filamentation[J]. mBio,2017,8(6): e01991-17.
[22] GUO D,YUE H,WEI Y,et al. Genetic regulatory mechanisms of Candida albicans biofilm formation[J]. Shengwu gongcheng xuebao,2017,33(9):1567-1581.
[23] MARTIN H,KAVANAGH K,VELASCO-TORRIJOS T. Targeting adhesion in fungal pathogen Candida albicans[J]. Future Med Chem,2021,13(3):313-334.
[24] XU Z,HUANG T,MIN D,et al. Regulatory network controls microbial biofilm development, with Candida albicans as a representative: from adhesion to dispersal[J].Bioengineered,2022,13(1):253-267.
[25] BEKTIC J,LELL C P,FUCHS A,et al. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro[J]. FEMS Immunol Med Microbiol,2001,31(1):65-71.
[26] LOHSE M B,GULATI M,CRAIK C S,et al. Combination of antifungal drugs and protease inhibitors prevent Candida albicans biofilm formation and disrupt mature biofilms[J]. Front Microbiol,2020,11:1027.DOI: 10.3389/fmicb.2020.01027.
[27] CORDEIRO R D A,SERPA R,MENDES P B L,et al. The HIV aspartyl protease inhibitor ritonavir impairs planktonic growth,biofilm formation and proteolytic activity in Trichosporon spp[J]. Biofouling (Chur,Switzerland),2017,33(8):640-650.
[28] ZDANAVICIENE E, SAKALAUSKIENE J, GLEIZNYS A, et al. Host responses to Candida albicans. A review[J]. Stomatologija, 2017,19(4):109-123.
[29] NAGLIK J R,KONIG A,HUBE B,et al. Candida albicans-epithelial interactions and induction of mucosal innate immunity[J]. Curr Opin Microbiol,2017,40:104-112.DOI: 10.1016/j.mib.2017.10.030.
[30] KOURJIAN G,RUCEVIC M,BERBERICH M J,et al. HIV protease inhibitor-induced cathepsin modulation alters antigen processing and cross-presentation[J].J Immunol,2016,196(9):3595-3607.
[31] PERICOLINI E, CENCI E, MONARI C, et al. Indinavir-treated Cryptococcus neoformans promotes an efficient antifungal immune response in immunosuppressed hosts[J]. Med Mycol, 2006,44(2):119-126.
[32] BEKTIC J,LELL C P,FUCHS A,et al. HIV protease inhibitors attenuate adherence of Candida albicans to epithelial cells in vitro[J]. FEMS Immunol Med Microbiol,2001,31(1):65-71.
[33] KANE A,CARTER D A. Augmenting azoles with drug synergy to expand the antifungal toolbox[J]. Pharmaceuticals (Basel),2022,15(4):482.
[34] ELDESOUKY H E,SALAMA E A,LANMAN N A,et al. Potent synergistic interactions between lopinavir and azole antifungal drugs against emerging multidrug-resistant Candida auris[J]. Antimicrob Agents Chemother,2020,65(1):e00684-20.
[35] BRILHANTE R S,CAETANO E P,RIELLO G B,et al. Antiretroviral drugs saquinavir and ritonavir reduce inhibitory concentration values of itraconazole against Histoplasma capsulatum strains in vitro[J]. Braz J Infect Dis,2016,20(2):155-159.
[36] FENG W,YANG J,MA Y,et al. The effects of secreted aspartyl proteinase inhibitor ritonavir on azoles-resistant strains of Candida albicans as well as regulatory role of SAP2 and ERG11[J]. Immun Inflamm Dis, 2021,9(3):667-680.
[37] 赵晓琴. 白念珠菌SAP2及其酶抑制剂利托那韦在唑类药物耐药中的作用[D].太原: 山西医科大学, 2020.
[38] DOS SANTOS A L. HIV aspartyl protease inhibitors as promising compounds against Candida albicans[J]. World J Biol Chem,2010,1(2):21-30. |
